S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University

S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University

SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- The inaugural S2S China Symposium has announced the finalists of its 2026 program. Co-hosted by RA Capital Management and Qiming Venture Partners, S2S China is the China chapter of Science2Startup, an...

Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion

Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion

INCHEON, South Korea, Aug. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, long-term growth...

Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics

Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics

Out-licenses BxC-I17e, Exosome-Based Therapeutics for New Indications KRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments + Double-Digit Percentage Royalties SEOUL, South Korea, Feb. 19, 2025 /PRNewswire/ -- Brexogen, a leading...

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Initiative (NATi) to advance ribonucleic acid (RNA)-based therapeutic manufacturing process...

menu
menu